Chun Chin Chang1, MD; Norihiro Kogame2, MD; Taku Asano2, MD; Clemens von Birgelen3, MD, PhD; Manel Sabaté4, MD, PhD; Yoshinobu Onuma1,5, MD, PhD; Patrick W. Serruys6, MD, PhD
1. Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands; 2. Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; 3. Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, the Netherlands; 4. Department of Interventional Cardiology, Cardiovascular Institute, University Clinic Hospital, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; 5. Cardialysis B.V., Rotterdam, the Netherlands; 6. Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland
The BuMA Supreme™ (SINOMED, Tianjin, China) is a sirolimus-eluting stent that has a biodegradable PLGA-polymer coating with an electro-grafting base layer on a thin-strut (80 µm) cobalt-chromium platform1. The PIONEER trial is a randomised study assessing the efficacy and safety of the BuMA Supreme compared with the Resolute™ stent (Medtronic, Minneapolis, MN, USA). The primary endpoint was the non-inferiority of the BuMA Supreme in terms of the nine-month angiographic in-stent late lumen loss (LLL). At nine months, the BuMA Supreme had a significantly higher in-stent LLL than the Resolute stent (0.29±0.33 vs 0.14±0.37 mm)1. Nevertheless, ...
No account yet? Create my pcr account
Sign up for free!
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases
Coronary interventionsStents and scaffolds
Read next article
Outcomes of bioresorbable vascular scaffolds versus everolimus-eluting stents by coronary complexity: a sub-analysis of the AIDA trial